Study Reveals 10-20% Drop in Tylenol Use Among Pregnant Women Post-Trump Autism Claim
KVUE sits 30% above its 52-week low of $14.02 on light trading volume (0.2× avg).
Summary
A new study published in The Lancet indicates that Tylenol use among pregnant women declined by 10-20% following former President Trump's public statements linking the pain reliever to autism. This quantified drop in demand for a flagship product, even if temporary, represents a material impact on consumer behavior and brand perception for Kenvue. This news adds to the existing narrative of product risk for Kenvue, as its recent 10-K (2026-02-20) already highlighted "significant, expanding product liability lawsuits related to key products." While the article notes the decrease "appeared to wane after several weeks," the initial decline is significant and could necessitate increased marketing or public relations efforts. Traders should monitor Kenvue's future sales reports for Tylenol and any further public health messaging or legal developments related to acetaminophen safety.
At the time of this announcement, KVUE was trading at $18.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $34.8B. The 52-week trading range was $14.02 to $25.17. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.